Docetaxel Plus Imatinib Mesylate in Metastatic Breast Cancer

NCT00193180 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Imatinib
DRUG: Docetaxel

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]